For many people living with type 2 diabetes, treatment eventually reaches a frustrating crossroads. Despite multiple medications, including GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, glycemic targets may remain difficult to achieve. Meanwhile, bariatric surgery can produce major metabolic benefits, but its invasiveness limits acceptance for many patients. This treatment …
Read More »Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s
The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …
Read More »The Rise of “Double Diabetes”: Why More Adults With Type 1 Diabetes Are Developing Insulin Resistance
More adults living with type 1 diabetes are now developing obesity, insulin resistance, hypertension, and metabolic complications once linked mainly to type 2 diabetes. This growing overlap, often called double diabetes, is becoming a major concern for clinicians and patients alike. While insulin therapy remains essential for type 1 diabetes …
Read More »Beyond the FIB-4: Why Diabetes Care Is Becoming a Hepatology-Endocrinology Partnership
Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit. Instead, clinicians are entering an era where diabetes care and hepatology increasingly overlap, especially as metabolic dysfunction-associated steatotic liver disease, or MASLD, becomes …
Read More »When GLP-1 Therapy Plateaus: What Clinicians Should Do Next
Everything seems to be working perfectly until it suddenly isn’t. A patient is losing weight steadily, HbA1c levels are improving, and confidence is high during every follow-up visit. Then progress slows. The scale barely changes. Blood sugar readings stop improving. Patients start asking whether the medication has stopped working, while …
Read More »GLP-1 Therapy and Muscle Loss: Are We Overlooking Sarcopenia Risk?
Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …
Read More »Fragmented Care in the GLP-1 Era: What Happens When Multiple Providers Prescribe the Same Therapy?
A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners …
Read More »Will Generic GLP-1 Drugs Change Diabetes Care? What Clinicians Should Expect Next
The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are …
Read More »Do GLP-1 Drugs Improve Osteoarthritis Outcomes? What New Trials Suggest About Pain and Mobility
For many patients with obesity-related osteoarthritis, daily movement can feel like walking with a heavy backpack that never comes off. Joint pain limits exercise, reduced activity leads to more weight gain, and the cycle continues. However, new research is raising an important question: could GLP-1 therapies help break that cycle? …
Read More »Oral GLP-1 Therapy in 2026: Will Easier Administration Change When We Start Treatment?
Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity? In 2026, these oral GLP-1 medications are gaining attention for their simplified dosing and improved convenience. As newer formulations reduce traditional barriers, clinicians are beginning to rethink when to initiate …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.